Literature DB >> 18535935

Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.

Juqun Shen1, Zhenping Zhu.   

Abstract

Fresenius Biotech GmbH (licensed from TRION Pharma GmbH) is developing catumaxomab, a rat/murine hybrid, trifunctional, bispecific (anti-epithelial cell adhesion molecule and anti-CD3) mAb for the potential intravenous and intraperitoneal treatment of ovarian cancer, gastric cancer, malignant pleural effusion and other cancers, and also for malignant ascites associated with various cancers. In 2007, following the successful completion of a phase II/III clinical trial in patients with malignant ascites from various cancers, Fresenius filed for European approval. Catumaxomab is currently undergoing phase II clinical trials in patients with malignant ascites, ovarian and stomach cancer.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18535935

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  12 in total

Review 1.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ramakrishnan Ayloor Seshadri; Olivier Glehen
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 2.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

3.  Structural and functional characterization of the trifunctional antibody catumaxomab.

Authors:  Dirk Chelius; Peter Ruf; Patrick Gruber; Matthias Plöscher; Reinhard Liedtke; Eva Gansberger; Juergen Hess; Michael Wasiliu; Horst Lindhofer
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

4.  Palliative treatment of malignant ascites: profile of catumaxomab.

Authors:  Lila Ammouri; Eric E Prommer
Journal:  Biologics       Date:  2010-05-25

5.  Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.

Authors:  Peter Ruf; Michael Kluge; Michael Jäger; Alexander Burges; Constantin Volovat; Markus Maria Heiss; Jürgen Hess; Pauline Wimberger; Birgit Brandt; Horst Lindhofer
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

Review 6.  Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?

Authors:  Mahendra P Deonarain; Christina A Kousparou; Agamemnon A Epenetos
Journal:  MAbs       Date:  2009 Jan-Feb       Impact factor: 5.857

7.  Effects of EpCAM overexpression on human breast cancer cell lines.

Authors:  Johanna M Gostner; Dominic Fong; Oliver A Wrulich; Florian Lehne; Marion Zitt; Martin Hermann; Sylvia Krobitsch; Agnieszka Martowicz; Guenther Gastl; Gilbert Spizzo
Journal:  BMC Cancer       Date:  2011-01-31       Impact factor: 4.430

Review 8.  Site-specific functionalization of proteins and their applications to therapeutic antibodies.

Authors:  Remko van Vught; Roland J Pieters; Eefjan Breukink
Journal:  Comput Struct Biotechnol J       Date:  2014-02-14       Impact factor: 7.271

9.  A novel approach for rapid high-throughput selection of recombinant functional rat monoclonal antibodies.

Authors:  Qin Chen; Shengping Qiu; Huanhuan Li; Chaolong Lin; Yong Luo; Wenfeng Ren; Yidi Zou; Yale Wang; Ninghshao Xia; Chenghao Huang
Journal:  BMC Immunol       Date:  2018-12-04       Impact factor: 3.615

Review 10.  The evolving concept of cancer and metastasis stem cells.

Authors:  Irène Baccelli; Andreas Trumpp
Journal:  J Cell Biol       Date:  2012-08-06       Impact factor: 10.539
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.